Purpose of review: In this article, we consider advanced technologies for the management of diabetes.
Recent findings: Specifically, we pose the question of which should come first: an insulin pump (CSII) or a continuous glucose monitor (CGM)? Historical perspective on both insulin delivery and glucose measurement is provided. Recently published clinical trials are reviewed. Practical issues including quality of life, patient education, and out-of-pocket cost are discussed. Based on available evidence and clinical experience, we favor CGM as a first-line technology recommendation for the treatment of type 1 diabetes (T1D).
Keywords: Continuous glucose monitor; Diabetes; Hemoglobin A1C; Hypoglycemia; Insulin pump; Time in range.